Study of MLN8237 in Participants With Advanced Hematological Malignancies

Phase 1 Completed 58 enrolled Millennium Pharmaceuticals, Inc.

Non-randomizedParallel-groupQuadruple-blindTreatment

Summary

This is an open-label, multicenter, phase 1 study of MLN8237 in participants with advanced hematological malignancies for whom there are limited standard treatment options.

Timeline

Start: 2008-07-11
Primary completion: 2016-10-01
Completion: 2016-10-19

Publications

Kelly KR, Shea TC, Goy A, Berdeja JG, Reeder CB, McDonagh KT, Zhou X, Danaee H, Liu H, Ecsedy JA, Niu H, Benaim E, Iyer SP. Phase I study of MLN8237--investigational Aurora A kinase inhibitor--in relapsed/refractory multiple myeloma, non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs. 2014 Jun;32(3):489-99. doi: 10.1007/s10637-013-0050-9. Epub 2013 Dec 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alisertib	Small molecule	25 mg	Oral
Subject	Alisertib	Small molecule	30 mg	Oral
Subject	Alisertib	Small molecule	35 mg	Oral
Subject	Alisertib	Small molecule	40 mg	Oral
Subject	Alisertib	Small molecule	45 mg	Oral
Subject	Alisertib	Small molecule	50 mg	Oral
Subject	Alisertib	Small molecule	65 mg	Oral
Subject	Alisertib	Small molecule	90 mg	Oral

Study of MLN8237 in Participants With Advanced Hematological Malignancies

Summary

Timeline

Publications

Drugs

Indications